Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in CashChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Silence Therapeutics (SLN) Net Income (2020 - 2025)

Historic Net Income for Silence Therapeutics (SLN) over the last 7 years, with Q3 2025 value amounting to -$21.0 million.

  • Silence Therapeutics' Net Income rose 4651.43% to -$21.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$64.5 million, marking a year-over-year increase of 2320.54%. This contributed to the annual value of -$45.3 million for FY2024, which is 1562.71% up from last year.
  • As of Q3 2025, Silence Therapeutics' Net Income stood at -$21.0 million, which was up 4651.43% from -$27.4 million recorded in Q2 2025.
  • Silence Therapeutics' 5-year Net Income high stood at $12.3 million for Q4 2024, and its period low was -$39.2 million during Q3 2024.
  • For the 5-year period, Silence Therapeutics' Net Income averaged around -$16.5 million, with its median value being -$16.6 million (2021).
  • In the last 5 years, Silence Therapeutics' Net Income soared by 16622.85% in 2024 and then tumbled by 56837.47% in 2025.
  • Quarter analysis of 5 years shows Silence Therapeutics' Net Income stood at -$15.1 million in 2021, then dropped by 16.64% to -$17.7 million in 2022, then decreased by 5.23% to -$18.6 million in 2023, then surged by 166.23% to $12.3 million in 2024, then tumbled by 270.36% to -$21.0 million in 2025.
  • Its Net Income stands at -$21.0 million for Q3 2025, versus -$27.4 million for Q2 2025 and -$28.5 million for Q1 2025.